Cutaneous Reactions to Chemotherapy: Commonly Seen, Less Described, Little Understood

Dermatologic Clinics

Volumn 26, Issue 1, 2008, Pages 103-119

  Sanborn, Rachel E ^a   Sauer, David A ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CAPECITABINE; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MINOXIDIL; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; SORAFENIB; THALIDOMIDE; THIOTEPA; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ACRAL ERYTHEMA; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ECCRINE SQUAMOUS SYRINGOMETAPLASIA; ERYTHEMA; HIDRADENITIS; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; INCIDENCE; LICHENOID ERUPTION; MULTIPLE MYELOMA; NAIL DYSTROPHY; NEUTROPHILIC ECCRINE HIDRADENITIS; PAPULAR RASH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN DISCOLORATION; SKIN DISEASE; SKIN IRRITATION; SKIN MANIFESTATION;

ANTINEOPLASTIC AGENTS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; IRRITANTS; NEOPLASMS; SKIN; SKIN DISEASES;

EID: 36048990863     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.08.006     Document Type: Review

References (109)

1. Susser W.S., Whitaker-Worth D.L., and Grant-Kels J.M. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40 (1999) 367-398
2. Alley E., Green R., and Schuchter L. Cutaneous toxicities of cancer therapy. Current Opinion in Oncology 14 (2002) 212-216
3. Weedon D. Skin pathology. 2nd edition. (2002), Elsevier Science Ltd, Edinbugh, UK
4. Hood A.F. Cutaneous side effects of cancer chemotherapy. Med Clin North Am 70 (1986) 187-209
5. Muller-Rover S., Rossiter H., Paus R., et al. Overexpression of Bcl-2 protects from ultraviolet B-induced apoptosis but promotes hair follicle regression and chemotherapy-induced alopecia. Am J Pathol 156 (2000) 1395-1405
6. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 16 (2006) 2505-2512
7. Strumberg D., Awada A., Hirte H., et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. Eur J Cancer 42 (2006) 548-556
8. In: Bolognia J.L., Jorizzo J.L., and Rapini R.P. (Eds). Dermatology (2003), Mosby, St. Louis (MO)
9. In: McKee P.H., Calonje E., and Granter S.R. (Eds). Pathology of the skin. 3rd edition. (2005), Mosby, St. Louis (MO)
10. Duvic M., Lemak N.A., Valero V., et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35 (1996) 74-78
11. Remlinger K.A. Cutaneous reactions to chemotherapy drugs: The art of consultation. Arch Dermatol 139 (2003) 77-81
12. Demircay Z., Gurbuz O., Alpdogan T.B., et al. Chemotherapy-induced acral erythema in leukemic patients: A report of 15 cases. Int J Dermatol 36 (1997) 593-598
13. Baack B.R., and Burgdorf W.H.C. Chemotherapy-induced acral erythema. J Am Acad Dermatol 24 (1991) 457-461
14. Waltzer J.F., and Flowers F.P. Bullous variant of chemotherapy-induced acral erythema. Arch Dermatol 129 (1993) 43-44
15. Hellier I., Bessis D., Sotto M.A., et al. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 132 (1996) 590-591
16. Sorscher S.M. Penile involvement with hand-foot syndrome. Am J Clin Dermatol 5 (2004) 209-210
17. Zimmerman G.C., Keeling J.H., Burris H.A., et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 131 (1995) 202-206
18. Lai S.E., Kuzel T., and Lacouture M.E. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 25 (2007) 341-346
19. Wyatt A.J., Leonard G.D., and Sachs D.L. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 7 (2006) 45-63
20. Cohen P.R. Acral erythema: a clinical review. Cutis 51 (1993) 175-179
21. Chung N.M., Gutierrez M., and Turner M.L. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol 142 (2006) 1510-1511
22. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1999) 485-493
23. Hoff P.M., Valero V., Ibrahim N., et al. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 82 (1998) 965-969
24. Schey S.A., Cooper J., and Summerhayes M. The "hand-foot syndrome" occurring with chronic administration of etoposide. Eur J Haematol 48 (1992) 118-119
25. Lotem M., Hubert A., Lyass O., et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136 (2000) 1475-1480
26. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
27. Vail D.M., Chun R., Thamm D.H., et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4 (1998) 1567-1571
28. Banfield G.K., Crate D., and Griffiths C.L. Long-term sequelae of palmar-plantar erythrodysaeshesia syndrome secondary to 5-fluorouracil therapy. J Royal Society of Med 88 (1995) 356P-357P
29. Flynn T.C., Harrist T.J., Murphy G.F., et al. Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia. J Am Acad Dermatol 11 (1984) 584-590
30. Brehler R., Reimann S., Bonsmann G., et al. Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Am J Dermatopathol 19 (1997) 73-78
31. Koppel R.A., and Boh E.E. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321 (2001) 327-335
32. Pierson J.C., Helm T.N., Taylor J.S., et al. Neutrophilic eccrine hidradenitis heralding the onset of acute myelogenous leukemia. Arch Dermatol 129 (1993) 791-792
33. Bernstein E.F., Spielvogel R.L., and Topolsky D.L. Recurrent neutrophilic eccrine hidradenitis. Br J Dermatol 127 (1992) 529-533
34. Shear N.H., Knowles S.R., Shapiro L., et al. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol 35 (1996) 819-822
35. Eich D., Scharffetter-Kochanek, Eich H.T., et al. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 25 (2002) 599-602
36. Chun Y.-S., Chang S.N., Oh D., et al. A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation. J Am Acad Dermatol 43 (2000) 358-360
37. Chu C.-Y., Yang C.-H., Yang C.-Y., et al. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 142 (2000) 808-811
38. Valks R., Fraga J., Porras-Luque J., et al. Chemotherapy-induced eccrine squamous syringometaplasia: a distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol 133 (1997) 873-878
39. Rubeiz N.G., Salem Z., Dibbs R., et al. Bleomycin-induced urticarial flagellate drug hypersensitivity reaction. Int J Dermatol 38 (1999) 140-141
40. Lindae M.L., Hu C.H., and Nickoloff B.J. Pruritic erythematous linear plaques on the neck and back. Arch Dermatol 12 (1987) 393-398
41. Scheulen M.E., Hilger R.A., Oberhoff C., et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6 (2000) 4209-4216
42. Falkson G., and Schulz E.J. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 74 (1962) 229-236
43. Schrijvers D., Van den Brande J., and Vermorken J.B. Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 142 (2000) 1069-1070
44. Prussick R., Thibault A., and Turner M.L. Recall of cutaneous toxicity from fluorouracil. Arch Dermatol 129 (1993) 644-645
45. Allen B.J., Parker D., Wright A.L., et al. Reticulate pigmentation due to 5-fluorouracil. Int J Dermatol 34 (1995) 219-220
46. Smith K.J., Germain M., and Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 6 (2002) 535-540
47. Ee H.-L., and Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 207 (2003) 196-198
48. Shapiro J., and Richardson G.E. Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol 12 (1994) 2237-2238
49. Stratman E.J. Chemotherapy recall reactions. J Am Acad Dermatol 46 (2002) 797
50. Mallory S.B., and Berry D.H. Severe reactivation of sunburn following methotrexate use. Pediatrics 78 (1986) 514-515
51. Westwick T.J., Sheretz E.F., McCarley D., et al. Delayed reactivation of sunburn by methotrexate: sparing of chronically sun-exposed skin. Cutis 39 (1987) 49-51
52. Korossy KS, Hood AF. Methotrexate reactivation of sunburn reaction. Arch Dermatol 2981; 117: 310-1.
53. Parry B.R. Radiation recall induced by tamoxifen. Lancet 340 (1992) 49
54. Solberg L.A., Wick M.R., and Bruckman J.E. Doxorubicin-enhanced skin reaction after whole-body electron-beam irradiation for leukemia cutis. Mayo Clin Proc 55 (1980) 711-715
55. Breza T.S., Halprin K.M., and Taylor R. Photosensitivity reaction to vinblastine. Arch Dermatol 111 (1975) 1168-1170
56. Vogler W.R., Huguley C.M., and Kerr W. Toxicity and antitumor effect of divided doses of methotrexate. Arch Intern Med 115 (1965) 285-293
57. Treudler R., Georgieva J., Ceilen C.C., et al. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. J Am Acad Dermatol 50 (2004) 783-785
58. Johnson T.M., Rapini R.P., and Duvic M. Inflammation of actinic keratoses from systemic chemotherapy. J Am Acad Dermatol 17 (1987) 192-197
59. Lacouture M.E., Desai A., Soltani K., et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 31 (2006) 783-785
60. Ener R.A., Meglathery S.B., and Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 15 (2004) 858-862
61. Berghammer P., Pohnl R., Baur M., et al. Docetaxel extravasation. Support Care Cancer 9 (2001) 131-134
62. Rudolph R., and Larson D.L. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5 (1987) 1116-1126
63. Bertelli G., Gozza A., Forno G.B., et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13 (1995) 2851-2855
64. Gault D.T. Extravasation injuries. Br J Plast Surg 40 (1993) 91-96
65. Lauvin R., Miglianico L., and Hellegouarc'h R. Skin cancer occurring 10 years after the extravasation of doxorubicin. N Engl J Med 332 (1995) 754
66. Sauerland C., Engelking C., Wickham R., et al. Vesicant extravasation part 1: mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 33 (2006) 1134-1141
67. Vargel I., Erdem A., Ertoy D., et al. Effects of growth factors on doxorubicin-induced skin necrosis: documentation of histomorphological alterations and early treatment by GM-CSF and G-CSF. Ann Plast Surg 49 (2002) 646-653
68. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf 12 (1995) 245-255
69. Bertelli G., Dini D., Forno G.B., et al. Hyaluronidase as an antidote to extravasation of vinca alkaloids: clinical results. J Cancer Res Clin Oncol 120 (1994) 505-506
70. Langer S.W., Sehested M., and Jensen P.B. Dexrazoxane is a potent and specific inhibitor of anthracycline-induced subcutaneous lesions in mice. Clin Cancer Res 6 (2000) 3680-3686
71. Saltz L.B., Meropol N.J., Loehrer P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
72. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
73. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
74. Brauer M.J., McEvoy B.F., and Mitus W.J. Hypersensitivity to nitrogen mustards in the form of erythema multiforme. Arch Intern Med 120 (1967) 499-503
75. Spencer H.J. Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil. J Surg Oncol 26 (1984) 47-50
76. MacGregor J.L., Silvers D.N., Grossman M.E., et al. Sorafenib-induced erythema multiforme. J Am Acad Dermatol 56 (2007) 527-528
77. Brodsky A., Aparici I., Argeri C., et al. Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity. J Clin Pharmacol 29 (1989) 821-823
78. Lee T.C., Hook C.C., and Long H.J. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin Proc 69 (1994) 80-82
79. Horowitz S.B., and Stirling A.L. Thalidomide-induced toxic epidermal necrolysis. Pharmacotherapy 19 (1999) 1177-1180
80. Rajkumar S.V., Gertz M.A., and Witzig T.E. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343 (2000) 972-973
81. Wookenstein P., Latarjet J., Roujeau J.-C., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352 (1998) 1586-1589
82. Hall V.C., El-Azhary R.A., Bouwhuis S., et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 48 (2003) 548-552
83. Purpora D., Ahern M.J., and Silverman N. Toxic epidermal necrolysis after mithramycin. N Engl J Med 299 (1978) 1412
84. Ozkan A., Apak H., Celkan T., et al. Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside. Pediatr Dermatol 18 (2001) 38-40
85. Nguyen T.V., and Margolis D.J. Hydroxyurea and lower leg ulcers. Cutis 52 (1993) 217-219
86. Kennedy B.J., Smith L.R., and Goltz R.W. Skin changes secondary to hydroxyurea therapy. Arch Dermatol 111 (1975) 183-187
87. Daoud M.S., Gibson L.E., and Pittelkow M.R. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 36 (1997) 178-182
88. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
89. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
90. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
91. Shepherd F.A., Pereira J.R., Cuileanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
92. Mendelsohn J. Epidermal growth factor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3 (1997) 2703-2707
93. Busam K.J., Capodieci P., Motzer R., et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144 (2001) 1169-1176
94. Van Doorn R., Kirtschig G., Scheffer E., et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147 (2002) 598-601
95. King L.E., Gates R.E., Stoscheck C.M., et al. The EGF/TGF alpha receptor in skin. J Invest Dermatol 94 Supp 6 (1990) 164S-170S
96. Perez-Soler R., Delord J.P., Halpern A., et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356
97. Hansen L.A., Alexander N., Hogan M.E., et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 150 (1997) 1959-1975
98. Segaert S., and Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16 (2005) 1425-1433
99. Dueland S., Sauer T., Lund-Johansen F., et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 42 (2003) 345-346
100. Morse L., and Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs 22 (2006) 152-162
101. Threadgill D.W., Dlugosz A.A., Hansen L.A., et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269 (1995) 230-234
102. Du X., Tabeta K., Hoebe K., et al. Velvet, a dominant EGFR mutation that causes wavy hair and defective eyelid development in mice. Genetics 166 (2004) 331-340
103. Pratt C.B., and Shanks E.C. Hyperpigmentation of nails from doxorubicin. JAMA 228 (1974) 460
104. Shah P.C., Rao K.R., and Patel A.R. Cyclophosphamide induced nail pigmentation. Br J Dermatol 98 (1978) 675-680
105. Llombart-Cussac A., Pivot X., and Spielmann M. Docetaxel chemotherapy induces transverse superficial loss of the nail plate. Arch Dermatol 133 (1997) 1466-1467
106. Slee P.H. Nail changes after chemotherapy. N Engl J Med 337 (1997) 168
107. Chapman S., and Cohen P.R. Transverse leukonychia in patients receiving cancer chemotherapy. South Med J 90 (1997) 395-398
108. Makris A., Mortimer P., and Powles T.J. Chemotherapy-induced onycholysis. Eur J Cancer 32A (1996) 374-375
109. Hussain S., Anderson D.N., Salvatti M.E., et al. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 88 (2000) 2367-2371